biological source
mouse
conjugate
unconjugated
antibody form
culture supernatant
antibody product type
primary antibodies
clone
MRQ-3, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (221M-14), vial of 0.5 mL concentrate (221M-15), bottle of 1.0 mL predilute (221M-17), vial of 1.0 mL concentrate (221M-16), bottle of 7.0 mL predilute (221M-18)
manufacturer/tradename
Cell Marque®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
isotype
IgG1
control
hairy cell leukemia
shipped in
wet ice
storage temp.
2-8°C
visualization
cytoplasmic, membranous
General description
ANXA1 is strongly expressed on the cell membrane and occasionally in the cytoplasm of tumor cells in 97% of samples from patients with hairy cell leukemia. By contrast, B-cell lymphomas other than hairy cell leukemia, including typical splenic lymphoma with villous lymphocytes and patients with variant hairy cell leukemia—as defined by current morphologic, phenotypic, and clinical criteria—are ANXA1-negative. In a study by Falini et al. ANXA1 immunodetection was 100% sensitive and specific for hairy cell leukemia. Normal B cells from different lympho-hemopoietic tissues were ANXA1-negative. In this study the expression of ANXA1 in myeloid cells, macrophages, or T-cell subset served as positive control. These findings validated the results of gene expression profiling in hairy cell leukemia at the protein level by showing that ANXA1 is consistently expressed in this type of leukemic disease, but not in other B-cell lymphomas. Of note is that negativity for ANXA1 was also present in patients with splenic lymphoma with villous lymphocytes, variant hairy cell leukemia, prolymphocytic leukemia, marginal zone and lymphoplasmacytoid lymphomas. Thus, ANXA1 is a molecule specific to hairy cell leukemia that can be used to differentiate this disease from other B-cell lymphomas. Wang et al. showed that high ANXA1 expression is frequent in esophageal and esophagogastric junction adenocarcinomas, is associated with more advanced pathologic T stage and the presence of distant metastasis, and is an independent prognostic factor for patient survival.
Associated products: TRAcP, T-bet.
Associated products: TRAcP, T-bet.
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Analysis Note
![]() IVD | ![]() IVD | ![]() IVD | ![]() RUO |
Other Notes
Annexin A1 Positive Control Slides, Product No. 221S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
试用我们的 产品选型工具 工具缩小选择范围
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable



